Search
forResearch 10 of 1000+
- Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
- Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
- Glycyrrhizic Acid Alleviates Osimertinib‐Induced Cutaneous Toxicity by Inhibiting Keratinocyte Apoptosis and Inflammation
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- Cutaneous toxicities of cancer therapy
- Cutaneous toxicities of new treatments for melanoma
- Cutaneous Toxicities From Transplantation-Related Medications
- Network pharmacology-based preventive effect of XZF on cutaneous toxicities induced by EGFR inhibitor
- Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib
- P164 Cutaneous toxicities occurring during amivantamab treatment: the experience of a single large specialist institution
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →